Can the ResMed share price smash its all-time high?

The ResMed Inc. (ASX: RMD) share price is down 18% from its all-time high, which may represent a buying opportunity.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A leading company in an important industry ResMed Inc. (ASX: RMD) is a leader in the sleep treatment market, with a range of cloud enabled products designed to care for people with sleep apnea, COPD and other chronic diseases. This leading position has resulted in the the company's share price growing at an annualised rate of 17.9% over the last decade, excluding dividends.

Healthcare continues to rise in importance as a major topic on social and political agendas around the world. Aging populations, an increase in chronic disease, growing costs and a shortage of doctors require better solutions and technologies.

Despite this the ResMed share price dropped after an underwhelming second quarter result, delivered on 24 January 2019. For Q2 the company delivered 9% revenue growth to $651 million (on a constant currency basis) and Non-GAAP operating profit growth of 15%, to $181 million.

Capital allocation

It is pleasing to see the company focus on the long term, with a stated strategy to 2025. ResMed invests approximately 7% of its revenue back into research & development. This helps the company maintain and grow its market share through its range of quality products.

ResMed isn't just investing in itself however, with a number of acquisitions being made in recent years. The company has made numerous acquisitions in its key field of sleep apnea – most recently the purchase of South Korean based HB Healthcare, on 7 March 2019. ResMed has also invested in emerging areas such as out-of-hospital software-as-a-service offerings, through its 5 November 2018 acquisition of MatrixCare. The strategic decisions on the growing digital health and software-as-a-service trends highlights an understanding of where healthcare is moving.

The patent dispute

One concern that was lingering with ResMed until 21 February 2019 was the ongoing patent infringement dispute between ResMed and Fisher & Paykel Healthcare Corp Limited (ASX: FPH). In February both companies agreed to settle all of their outstanding patent infringement disputes, in all venues around the world. Most of the terms are confidential however, all ongoing proceedings ceased and both companies are paying their own legal expenses.

Foolish bottom line

ResMed has a long runway for growth, with sleep apnea being a grossly under-diagnosed medical condition. As doctors and potential patients alike become more aware of the condition, ResMed should see a steady increase in the adoption of its CPAP machines and its share price.

ResMed will report its third quarter FY19 earnings on 2 May 2019.

If you like the sound of ResMed, here are some other high quality growth companies.

Motley Fool contributor Lloyd Prout owns shares in ResMed. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

The worst 3 ASX 200 stocks to buy and hold in October unmasked

You would have done well to avoid these three ASX 200 stocks in October.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why AFT, Amcor, Corporate Travel, and Macquarie shares are falling today

These shares are ending the week in the red. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why AGL, Imugene, Star, and Woolworths shares are dropping today

These shares are dropping on Thursday. Let's see why investors are selling them.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Fallers

Why Corporate Travel Management, JB Hi-Fi, Mineral Resources, and Syrah shares are rising

These shares are having a strong session. Why are investors buying their shares?

Read more »

A guys points his fingers down.
Share Fallers

Why Brainchip, Cettire, Star, and Woolworths shares are being sold off today

These shares are having a difficult time on hump day. But why?

Read more »

Three guys in shirts and ties give the thumbs down.
Share Fallers

Why Black Cat, BlueScope, Cettire, and Coronado shares are falling today

These shares are missing out on the good times on Tuesday. But why?

Read more »

a business man in a suit holds his hand over his eyes as he bows his head in a defeated post suggesting regret and remorse.
Share Fallers

Why Adriatic Metals, Metcash, Paladin Energy, and Westgold shares are tumbling today

These shares are starting the week in the red. But why?

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Down 36% in 3 weeks, why is the Mineral Resources share price getting hammered again on Friday?

ASX investors are bidding down Mineral Resources shares again on Friday.

Read more »